The Sentinel


Friday, April 15, 2022

Letter from the Editor - April

Hello JITC Readers,


In the northern hemisphere, spring is in the air and conference season is just beginning. Many of you stopped by to say hello to Deputy Editor-in-Chief at the SITC booth during the AACR annual meeting earlier this month. It is wonderful to see colleagues as we cautiously return to more frequent travel and in-person meetings.

If you are unable to take advantage of a face-to-face meeting, however, JITC is pleased to offer you a series of video resources featuring our editors answering commonly-asked questions about the types of content the journal seeks as well as how and where to submit your manuscript. You can find all the videos on JITC’s YouTube playlist.

This month’s highlights include three original research articles and one short report.

Kristin G Anderson and colleagues report an innovative engineering approach to subvert activation-induced cell death signaling in the tumor microenvironment in order to enhance proliferation and survival of chimeric antigen receptor T cells.

A radiomic biomarker based on pre-treatment CT images developed by Khalid Jalzieh et al predicted survival outcomes with chemoradiotherapy followed by consolidation durvalumab for unresectable stage III non-small cell lung cancer.

Peng Li and colleagues describe epigenetic regulation of T cell exhaustion markers mediated by signaling through the vitamin D receptor, with accompanying clinical trial data from patients with non-small cell lung cancer receiving calcitriol supplementation along with docetaxel.

Mechanistic rationale for transient MEK inhibition to alleviate immunosuppression in the head and neck cancer tumor microenvironment prior to anti-PD-1 therapy is described by Manu Prasad et al.

If you are looking to further your reading this month, you can also peruse popular articles from the past years in the archive feature in this edition of the digest.



Pedro J. Romero, MD
Editor-in-Chief, Journal for ImmunoTherapy of Cancer